Caitong International Asset Management’s Astria Therapeutics ATXS Stock Holding History

Caitong International Asset Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,067	Closed	-$106K	–	2601
2025 Q4	$106K	Buy	+8,067	New	+$96.4K	0.03%	399
2025 Q3	–	Sell	-23	Closed	-$123	–	1945
2025 Q2	$123	Sell	23 -892	-97%	-$4.32K	﹤0.01%	1824
2025 Q1	$4.89K	Buy	915 +860	+1,564%	+$6.02K	﹤0.01%	1025
2024 Q4	$492	Buy	+55	New	+$584	﹤0.01%	1468

Caitong International Asset Management's ATXS Position: Q1 2026 in Review

Caitong International Asset Management sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 8,067 shares — an estimated $106K sold.

Caitong International Asset Management first reported a position in ATXS in Q4 2024 and held it in 4 quarters. The position peaked at $106K in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Caitong International Asset Management reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Caitong International Asset Management sold 8,067 Astria Therapeutics shares in Q1 2026, an estimated $106K.
Caitong International Asset Management first reported a position in Astria Therapeutics in Q4 2024 and held it in 4 quarters.
Caitong International Asset Management's Astria Therapeutics position peaked at $106K in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.